» Articles » PMID: 32404067

Role of the Initial Degree of Anaemia and Treatment Model in the Prognosis of Gastric Cancer Patients Treated by Chemotherapy: a Retrospective Analysis

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2020 May 15
PMID 32404067
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Anaemia is highly prevalent in gastric cancer (GC) patients. The role of initial haemoglobin levels in predicting the prognosis of GC patients treated by chemotherapy has not been well determined. Our present study aims to evaluate the relationship between the degree of anaemia and the overall survival (OS) and progression-free survival (PFS) of patients with GC.

Methods: Our retrospective study enrolled 598 patients who were treated with chemotherapy when the recurrent or metastatic GCs were unsuitable for surgical resection. Univariate and multivariate analyses were performed to identify risk factors that had the potential to affect patient prognosis. Additionally, the relationship between clinicopathological characteristics, including treatment method, and degree of cancer-related reduction in haemoglobin was further analysed.

Results: Our results revealed that patients with HB level ≤ 80 g/L had a trend toward a shortened median OS and PFS (p = 0.009 and p = 0.049, respectively). Interestingly, we also found that HB ≥ 30 g/L was associated with a significantly shortened median OS and PFS (p = 0.039 and p = 0.001, respectively). Multivariate analysis showed that HB levels ≤80 g/L could be used as an independent prognostic factor for recurrent and metastatic GC. More importantly, HB ≥ 30 g/L and treatment response were also significantly associated with OS and PFS. Furthermore, the degree of haemoglobin decrease was associated with chemotherapy including platinum and the number of chemotherapy cycles.

Conclusion: Our study concludes that the initial degree of anaemia and a decrease in haemoglobin of ≥30 g/L can serve as biomarkers to predict prognosis in recurrent or metastatic GC patients, while chemotherapy treatment rather than red blood cell (RBC) transfusion can improve their prognosis. Additionally, platinum should not be recommended for treating severely anaemic GC patients.

Citing Articles

ILF2 protein is a promising serum biomarker for early detection of gastric cancer.

Liu S, Wang J, Liu M, Guo D, Wen Q, Liang Y BMC Cancer. 2024; 24(1):1447.

PMID: 39587551 PMC: 11587746. DOI: 10.1186/s12885-024-13205-6.


Intravenous iron and iron deficiency anemia in patients with gastrointestinal cancer: A systematic review.

Nandakumar S, Singh N, Tharani A, Pankiw M, Brezden-Masley C PLoS One. 2024; 19(5):e0302964.

PMID: 38776289 PMC: 11111077. DOI: 10.1371/journal.pone.0302964.


Gastric adenocarcinoma with high‑level microsatellite instability: A case report.

Alfaro A, Zanabria D, Aguilar A, Jimenez-Solano S, Zevallos A, Fajardo W Mol Clin Oncol. 2023; 18(3):16.

PMID: 36798468 PMC: 9926044. DOI: 10.3892/mco.2023.2612.

References
1.
Nishino M, Jackman D, Hatabu H, Yeap B, Cioffredi L, Yap J . New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010; 195(3):W221-8. PMC: 3130298. DOI: 10.2214/AJR.09.3928. View

2.
Hironaka S, Sugimoto N, Yamaguchi K, Moriwaki T, Komatsu Y, Nishina T . S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2015; 17(1):99-108. DOI: 10.1016/S1470-2045(15)00410-6. View

3.
Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T . Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG.... J Clin Oncol. 2013; 31(35):4438-44. DOI: 10.1200/JCO.2012.48.5805. View

4.
Ye X, Liu J, Chen Y, Wang N, Lu R . The impact of hemoglobin level and transfusion on the outcomes of chemotherapy in gastric cancer patients. Int J Clin Exp Med. 2015; 8(3):4228-35. PMC: 4443168. View

5.
Aapro M, Jelkmann W, Constantinescu S, Leyland-Jones B . Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer. 2012; 106(7):1249-58. PMC: 3314780. DOI: 10.1038/bjc.2012.42. View